GN-CORPORATION
19.10.2020 09:57:06 CEST | Business Wire | Press release
Sufyan Ibrahim and Himanshu Yashavanthi Nagesh of Kasturba Medical College, India, won the prestigious Fujio Cup Quiz (FCQ), an active knowledge gaining academic event of NCRM NICHE 2020, on stem cells and regenerative medicine, in a toughly fought contest among teams representing Monash University, Australia, Birla Institute of Technology (BITS-Pilani), India and Bandung Institute of Technology, Indonesia, who came second . The virtual event had lectures by Prof. Masaharu Seno, Okayama University on induced pluripotent stem cells, Dr Maria Nostro, University of Toronto on pancreatic progenitors for diabetes and Fr Francis Xavier, Loyola College, Chennai in the inter-disciplinary conclave on stress management during Covid-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005298/en/
Regenerative Medicine is a specialty demanding inter-disciplinary interaction, as physical forces like gravity and elasticity, chemically synthesized polymers and nanomaterial scaffolds, provide suitable micro environment to the cells for in vitro culture in the lab, which are transplanted to replace, restore, repair and regenerate tissues to address organ failures. FCQ, a part of NCRM NICHE started in 2006 is conducted in Tokyo, Japan, since 2017 in which young scholars of different specialties of science from all over the world participate, cross several steps of quizzing and assignments to win the trophy. Alumni of top scoring teams of FCQ (FCQ elites) are eligible to nominate candidates to Edogawa NICHE Prize (www.edogawanicheprize.org ). The Joyce and James Till Travel Grant (www.j2t2grant.org ) instituted in 2018, with a grant by Prof. James Till, 2018 Edogawa NICHE Prize recipient, was awarded this year to Dr. Rupesh Kumar Natarajan, (2013 FCQ elite), now pursuing fellowship in pediatric cardiology, University of Minnesota, USA.
FCQ as an innovation platform, has started attracting multinational companies for collaboration following development of novel solutions like BEES-HAUS for urethral stricture (https://onlinelibrary.wiley.com/doi/full/10.1111/iju.13852 ), cartilage repair (https://www.sciencedirect.com/science/article/pii/S2352320420300274 ) and the recently granted patent on microgravity based enhancement of nitric oxide synthesis by blood cells, specially NK cells.
Dr. Shojiro Katoh, (Founder, EELS) congratulated the winners and hopes to invite to Japan beside honoring the 2020 Edogawa NICHE Prize recipient Dr. John Venter in the coming years, by when the Boron Neutron Capture Therapy (BNCT) in Edogawa Hospital (http://bnct-cancer.com/center.php ) could be ready to offer treatment to cancer patients from abroad and start research collaboration with overseas institutes. Event information will be updated in: www.ncrmniche.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005298/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience23.2.2026 15:13:00 CET | Press release
Express Access, Party Favors, and Private Room with Decorations and Ghirardelli Ice Cream Sundaes Parents who have looked for the best birthday party idea for their children have had their wish fulfilled. Today, the Empire State Building (ESB) announced the debut of its first-ever ESB Birthday Party Package for kids at the international icon’s Observatory as part of year-long 95th anniversary celebrations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223161708/en/ The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience “From Lego playtime to Percy Jackson readers, children love the Empire State Building and now parents can give an unmatched experience to their children and their friends,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. “This birthday party package tops them all with an escorted visit through our world-fa
Xsolla Co-Sponsors Gamescom Dev Leadership Summit in Lisbon, Bringing Together Gaming Industry Leaders to Shape the Future of Game Development23.2.2026 15:00:00 CET | Press release
Platform Supporting 1,500+ Game Developers Across 200+ Geographies to Host Networking Dinner and Co-Moderate Strategic Roundtable at Premier European Gaming Executive Summit Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its co-sponsorship of the Gamescom Dev Leadership Summit Lisbon, taking place February 24-26 at SUD Lisboa in Portugal. The event brings together gaming industry executives, studio founders, and business leaders to explore opportunities and innovations shaping the future of game development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223253705/en/ Graphic: Xsolla As part of its sponsorship, Xsolla will host the summit's Wednesday evening networking dinner and co-moderate a strategic roundtable session focused on business models and sustainable growth in the gaming industry. "We're seeing incredible innovation from studios acro
CoolMPS™ 600: Accurate and Affordable Long MPS/NGS Reads on a Mid-Throughput Platform23.2.2026 15:00:00 CET | Press release
Swiss Rockets AG announces that its CoolMPS 600 mid-throughput sequencer with advanced chemistry and novel MPS/NGS read length will become available in Q2 2026. Enabled by its exclusive license of CoolMPS technology, Swiss Rockets AG is developing its first sequencer, CoolMPS 600, through contract R&D with Complete Genomics since August 2025. The platform is utilizing the company’s proprietary antibody-based CoolMPS™ chemistry combined with DNBSEQ™, a real PCR-free DNA nanoarray technology. Separately, Swiss Rockets AG announced that it has entered into a definitive agreement to acquire 100% ownership of Complete Genomics. CoolMPS 600 enables cost-effective extended single-end sequencing to 600 bases (SE600) while maintaining high base accuracy. The system is designed to support advanced whole-genome sequencing (WGS) with improved mapping accuracy across complex genomic regions, including better detection of structural variants. It also enables full length transcriptomes and more infor
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 14:08:00 CET | Press release
Angelini Pharma secures exclusive global license rights to future identified drug targets Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.busine
Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 14:00:00 CET | Press release
DoD customers can now leverage Armis Centrix™ with enhanced security controls and connectivity Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom